Attention has been drawn recently by the IL-23/Th17 effector axis because of its potential as a therapeutic target and as a key passage to understanding the pathophysiology of psoriasis and IBD due to its synergy with intestinal mucosa cells and keratinocytes. This evidence concerns the gene IL37 and irritable bowel syndrome.